Momenta Pharmaceuticals, Inc. (MNTA)

[rwwine]

"That may be true; however, the case just decided by the District Court was about Teva’s IP, not MNTA’s."

You are correct sir, my mistake. I should have been much more specific. My opinionated statement was a general comment as to what I personally view in hindsight. Given all I have read, reviewed and understood, I specifically had come to the conclusion that the IP estate surrounding MNTA’s m-Lovenox was so superior, that companies like Amphastar had very little if any chance of FDA approval let alone market the product successfully. Today I know this was a gross mistake and assumption on my part and in no way am criticizing MNTA science or legal skills.

Additionally, I unfortunately assumed that given the tremendous amount of money invested by MNTA/NVA on developing IP for mCopaxone and a production strategy, that they (MNTA) had surely developed and patented IP that would lead to successful production without even coming close to infringing on TEVA’s IP.

I understand the landscape could change for MNTA over the next 1-2 years and they could prevail on these open unresolved legal cases. I am just expressing my “surprise” and disappointment if you will as to the events of the last 12 months and how I and perhaps other investors “may” not view MNTA proprietary technology as “superior” as I had at one time. As with all things, time will tell.